

**ANALYSIS OF AGREEMENT CONTAINING  
CONSENT ORDERS TO AID PUBLIC COMMENT**

In the Matter of Elanco Animal Health, Inc., a Bayer Animal Health, GmbH  
File No. 1910198

**I. Introduction**

The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) with Elanco Animal Health, Inc. (“Elanco”), assets for approximately \$7.6 billion. Both parties sell low-dose prescription treatments for canine otitis externa, fast-acting oral treatments that kill adult fleas on canines, and brand name cattle pour-on insecticides. The Commission alleges in its Complaint that the Proposed Acquisition, if consummated, would violate Section 5 of the Clayton Act, as amended, 15 U.S.C. 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. 45, by lessening competition in the U.S. markets for these three product categories.

The proposed Consent Agreement will remedy the alleged violations by preserving competition that would otherwise be eliminated by the Proposed Acquisition. Specifically, the terms of the proposed Consent Agreement, Elanco is required to divest its canine otitis externa treatment product, Osurnia, to Dechra Pharmaceuticals PLC (“Dechra”), its fast-acting oral treatment that kills adult fleas on canines, Sapstar, to PetIQ, Inc. (“PetIQ”), and its brand name cattle pour-on product, StandGuard, to Neogen Corporation (“Neogen”).

**II. The Relevant Products and Competitive Effects**

The Commission’s Complaint alleges three relevant product markets within which to analyze the Proposed Acquisition.

The first relevant product market is low-dose prescription treatments for canine otitis externa. Canine otitis externa is an inflammation of the outer ear caused by bacteria and fungi. Common symptoms of otitis externa include pain, itching, redness, scaling, and swelling of the ear canal and may result in serious complications if left untreated. Numerous prescription products treat canine otitis externa, but only the parties’ products—Elanco’s Osurnia and Bayer’s Claro—require only one or two doses to treat the condition. Bayer’s prescription otitis externa treatment product, Claro, is a single-dose otic solution, while Elanco’s product, Osurnia, is an otic gel given in two doses seven days apart. While other prescription products can be used to treat canine otitis externa, these other products require numerous applications to the ear canal to twice daily for 14 consecutive days and are thus not reasonable substitutes for the parties’ products, which are considerably more convenient to use. As such, the Proposed Acquisition

would create a monopoly by combining the only two low-dose prescription products that treat canine otitis externa.

A second relevant product market is fast-acting oral treatments that kill adult fleas on canines. While there are numerous products that prevent fleas on dogs, most are slow-acting or preventative, targeting flea larvae. In contrast, Elanco's Capstar and Bayer's Advantus start killing adult fleas quickly (within 30 minutes for Capstar, and within 60 minutes for Advantus) and eliminate all adult fleas within four hours. Medicated shampoos and sprays that can be used to kill adult fleas are much less convenient to administer and are slow-acting. As Elanco's Capstar and Bayer's Advantus are the only fast-acting oral treatments that kill adult fleas on canines, the Proposed Acquisition would also create a monopoly for fast-acting oral treatments that kill adult fleas on canines.

A third relevant product market is brand name cattle pour-on insecticides. Cattle pour-on insecticides are liquid parasitocides administered directly to cattle's skin that kill and deter biting flies, lice, and mites. Many customers trust and rely on brand name cattle pour-on insecticides rather than generic products. As a result, generic cattle pour-on insecticides are not a reasonable substitute for the parties' brand name cattle pour-on insecticides. The market for brand name cattle pour-on insecticides is highly concentrated. Bayer is the market leader, selling three cattle pour-on insecticide products (CleanUp II, Cylence, and Permethrin). The only other competitors with meaningful sales in the market are M&C Co., Inc., which sells four products, and Elanco, which sells StandGuard. Thus, the Proposed Acquisition would allow the th [(w)3 i9d1 (lacu -0

#### IV. The Agreement Containing Consent Order

The proposed Consent Agreement effectively remedies the Proposed Acquisition's anticompetitive effects in the three relevant product markets by requiring the parties to divest the rights and assets related to Elanco's products in each of the markets. The proposed Consent Agreement requires Elanco to divest Osrurnia to Dechra, Capstar to PetIQ, and StandGuard to Neogen. The Order requires Elanco to divest the relevant rights and interests in these products no later than ten days after the consummation of the Proposed Acquisition.

Dechra, headquartered in Northwich, England, is a global animal health company and is publicly traded on the London Stock Exchange. Dechra has significant presence and experience in the United States, operating in the United States for over 15 years and offering more than 80 U.S. products, including both prescription and over-the-counter prescription companion animal products. Osrurnia will complement Dechra's broad dermatology portfolio, which includes Animax Ointment, an antibacterial, antifungal, and anti-inflammatory skin application that is a daily use treatment and is indicated for multiple skin conditions, anal gland infections in dogs as well as canine otitis externa. Although Animax can treat canine otitis externa, it is not a direct competitor to Osrurnia given it is an older generation product requiring daily application to treat the condition.

PetIQ, headquartered in Boise, Idaho, is a rapidly growing pet health and wellness company. It has served as Elanco's exclusive distributor of Capstar to retailers since 2018. Capstar aligns well with the other products for dogs in PetIQ's portfolio. PetIQ's products include complementary flea and tick products for dogs that offer longer lasting treatments to kill eggs and larvae and are sold under the Sergeant's, Advecta, and Sentry brand names. PetIQ sells products through all the companion animal retail channels through which Elanco distributes Capstar and also sells its current product line to pet specialty retailers, mass merchandisers/grocery stores, and ecommerce sites.

Neogen, headquartered in Lansing, Michigan, is a global animal and food safety company offering a wide portfolio of solutions, including insecticides, diagnostic test kits to detect contamination in animal feed, animal pharmaceuticals, vaccines, and diagnostics for production animals. Neogen currently markets and sells its products through the same distribution channels Elanco uses for StandGuard. In addition, Neogen m

